Buscar
Lexaria Bioscience Corp
LEXXAñadir a la lista de seguimiento
0.391USD
-0.005-1.34%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
9.69MCap. mercado
PérdidaP/E TTM
Más Datos de Lexaria Bioscience Corp Compañía
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Información de Lexaria Bioscience Corp
Símbolo de cotizaciónLEXX
Nombre de la empresaLexaria Bioscience Corp
Fecha de salida a bolsaOct 28, 2009
Director ejecutivoChristopher (Richard)
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 28
Dirección100 - 740 Mccurdy Road
CiudadKELOWNA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV1X 2P7
Teléfono12507656424
Sitio Webhttps://www.lexariabioscience.com/
Símbolo de cotizaciónLEXX
Fecha de salida a bolsaOct 28, 2009
Director ejecutivoChristopher (Richard)
Ejecutivos de Lexaria Bioscience Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
555.46K
-18.00%
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
--
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
555.46K
-18.00%
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
--
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Lexaria Bioscience Corp?
Los cinco principales accionistas de Lexaria Bioscience Corp son: Mr. Christopher A. (Chris) Bunka
¿Cuántas instituciones poseen acciones de Lexaria Bioscience Corp (LEXX)?
A fecha de 2026Q1, 54 instituciones poseen acciones de Lexaria Bioscience Corp, con un valor de mercado combinado de aproximadamente 1.64M, lo que representa el 6.61% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2368419.00.